Abstract | BACKGROUND & AIMS: METHODS: RESULTS: Patients taking mesalamine tablets experienced a decrease of CDAI median score value of 113.5 (95% confidence interval [CI], 33-149) compared with 123 (95% CI, 77-155) in the mesalamine microgranular group and 154 (95% CI, 99-197) in the 6-methylprednisolone group (P = 0.07 [NS]). Remission at the final visit occurred in 19 of 31 (61%) patients taking steroids compared with 21 of 35 (60%) patients taking mesalamine tablets and 22 of 28 (79%) patients taking microgranular mesalamine (NS). Five patients on steroids were withdrawn because of side effects, and a case of pancreatitis was related to microgranular mesalamine. CONCLUSIONS:
Mesalamine in microgranular formulation seems to be equally as effective as a standard dosage of steroids in the treatment of the mild to moderate form of Crohn's ileitis.
|
Authors | C Prantera, M Cottone, F Pallone, V Annese, A Franzè, R Cerutti, G Bianchi Porro |
Journal | Gastroenterology
(Gastroenterology)
Vol. 116
Issue 3
Pg. 521-6
(Mar 1999)
ISSN: 0016-5085 [Print] United States |
PMID | 10029609
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Mesalamine
- Methylprednisolone
|
Topics |
- Adult
- Anti-Inflammatory Agents, Non-Steroidal
(adverse effects, therapeutic use)
- Crohn Disease
(drug therapy, physiopathology)
- Female
- Humans
- Ileitis
(drug therapy, physiopathology)
- Italy
- Male
- Mesalamine
(adverse effects, therapeutic use)
- Methylprednisolone
(adverse effects, therapeutic use)
|